UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies

Therapeutic Advances in Neurological Disorders, 2018-01, Vol.11, p.1756285617749134-1756285617749134

2018

Volltextzugriff (PDF)

From Traditional to Targeted Immunotherapy in Myasthenia Gravis: Prospects for Research

Frontiers in neurology, 2020-09, Vol.11, p.981-981

2020

Volltextzugriff (PDF)

Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic

Journal of the neurological sciences, 2020-05, Vol.412, p.116803-116803, Article 116803

2020

Volltextzugriff (PDF)

Targeting autoimmune mechanisms by precision medicine in Myasthenia Gravis

Frontiers in immunology, 2024-06, Vol.15, p.1404191

2024

Volltextzugriff (PDF)

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis

Neurology, 2019-06, Vol.92 (23), p.e2661

2019

Volltextzugriff (PDF)

Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis

Journal of neurology, 2023-06, Vol.270 (6), p.3129-3137

2023

Volltextzugriff (PDF)

Therapeutic efficacy of 3,4-Diaminopyridine phosphate on neuromuscular junction in Pompe disease

Biomedicine & pharmacotherapy, 2021-05, Vol.137, p.111357-111357, Article 111357

2021

Volltextzugriff (PDF)

Toll‐like receptors 7 and 9 in myasthenia gravis thymus: amplifiers of autoimmunity?

Annals of the New York Academy of Sciences, 2018-02, Vol.1413 (1), p.11-24

2018

Volltextzugriff (PDF)

Importance of Shank3 Protein in Regulating Metabotropic Glutamate Receptor 5 (mGluR5) Expression and Signaling at Synapses

The Journal of biological chemistry, 2011-10, Vol.286 (40), p.34839-34850

2011

Volltextzugriff (PDF)

Autoimmunity to neuronal nicotinic acetylcholine receptors

Pharmacological research, 2023-06, Vol.192, p.106790-106790, Article 106790

2023

Volltextzugriff (PDF)

Rozanolixizumab efficacy in generalised myasthenia gravis: Subgroup analyses from the randomised, phase 3, MycarinG study

Journal of neurology, neurosurgery and psychiatry, 2023-11, Vol.94 (Suppl 1), p.A82-A82

2023

Volltextzugriff (PDF)

miR-146a in Myasthenia Gravis Thymus Bridges Innate Immunity With Autoimmunity and Is Linked to Therapeutic Effects of Corticosteroids

Frontiers in immunology, 2020-03, Vol.11, p.142

2020

Volltextzugriff (PDF)

Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis

Annals of neurology, 2007-03, Vol.61 (3), p.219-227

2007

Volltextzugriff (PDF)

Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis

Neurology and therapy, 2023-10, Vol.12 (5), p.1435-1438

2023

Volltextzugriff (PDF)

Mutations associated with hypokalemic periodic paralysis: from hotspot regions to complete analysis of CACNA1S and SCN4A genes

Neurogenetics, 2022, Vol.23 (1), p.19-25

2022

Volltextzugriff (PDF)

Multiomic elucidation of a coding 99-mer repeat-expansion skeletal muscle disease

Acta neuropathologica, 2020-08, Vol.140 (2), p.231-235

2020

Volltextzugriff (PDF)

Reliability and Repeatability Analysis of Indices to Measure Gait Deterioration in MS Patients during Prolonged Walking

Sensors (Basel, Switzerland), 2020-09, Vol.20 (18), p.5063

2020

Volltextzugriff (PDF)

FM19G11-loaded nanoparticles modulate energetic status and production of reactive oxygen species in myoblasts from ALS mice

Biomedicine & pharmacotherapy, 2024-04, Vol.173, p.116380-116380, Article 116380

2024

Volltextzugriff (PDF)

Anti-fibrotic effect of pirfenidone in muscle derived-fibroblasts from Duchenne muscular dystrophy patients

Life sciences (1973), 2016-01, Vol.145, p.127-136

2016

Volltextzugriff (PDF)

Etiology of myasthenia gravis: Innate immunity signature in pathological thymus

Autoimmunity reviews, 2013-07, Vol.12 (9), p.863-874

2013

Volltextzugriff (PDF)

Complement Inhibition for the Treatment of Myasthenia Gravis

ImmunoTargets and therapy, 2020-01, Vol.9, p.317-331

2020

Volltextzugriff (PDF)

Immune Soluble Factors in the Cerebrospinal Fluid of Progressive Multiple Sclerosis Patients Segregate Into Two Groups

Frontiers in immunology, 2021-03, Vol.12, p.633167-633167

2021

Volltextzugriff (PDF)

Identification of a cytokine profile in serum and cerebrospinal fluid of pediatric and adult spinal muscular atrophy patients and its modulation upon nusinersen treatment

Frontiers in cellular neuroscience, 2022-08, Vol.16, p.982760-982760

2022

Volltextzugriff (PDF)

MiR-146a in ALS: Contribution to Early Peripheral Nerve Degeneration and Relevance as Disease Biomarker

International journal of molecular sciences, 2023-02, Vol.24 (5), p.4610

2023

Volltextzugriff (PDF)

Diagnosis and treatment of myasthenia gravis

Current opinion in rheumatology, 2019-11, Vol.31 (6), p.623-633

2019

Volltextzugriff (PDF)

1 – 25 von 365

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(346)
Mit Volltextzugriff
(294)

Publikationsform

Sprache

Englisch
(365)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies

From Traditional to Targeted Immunotherapy in Myasthenia Gravis: Prospects for Research

Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic

Targeting autoimmune mechanisms by precision medicine in Myasthenia Gravis

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis

Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis

Therapeutic efficacy of 3,4-Diaminopyridine phosphate on neuromuscular junction in Pompe disease

Toll‐like receptors 7 and 9 in myasthenia gravis thymus: amplifiers of autoimmunity?

Importance of Shank3 Protein in Regulating Metabotropic Glutamate Receptor 5 (mGluR5) Expression and Signaling at Synapses

Autoimmunity to neuronal nicotinic acetylcholine receptors

Rozanolixizumab efficacy in generalised myasthenia gravis: Subgroup analyses from the randomised, phase 3, MycarinG study

miR-146a in Myasthenia Gravis Thymus Bridges Innate Immunity With Autoimmunity and Is Linked to Therapeutic Effects of Corticosteroids

Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis

Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis

Mutations associated with hypokalemic periodic paralysis: from hotspot regions to complete analysis of CACNA1S and SCN4A genes

Multiomic elucidation of a coding 99-mer repeat-expansion skeletal muscle disease

Reliability and Repeatability Analysis of Indices to Measure Gait Deterioration in MS Patients during Prolonged Walking

FM19G11-loaded nanoparticles modulate energetic status and production of reactive oxygen species in myoblasts from ALS mice

Anti-fibrotic effect of pirfenidone in muscle derived-fibroblasts from Duchenne muscular dystrophy patients

Etiology of myasthenia gravis: Innate immunity signature in pathological thymus

Complement Inhibition for the Treatment of Myasthenia Gravis

Immune Soluble Factors in the Cerebrospinal Fluid of Progressive Multiple Sclerosis Patients Segregate Into Two Groups

Identification of a cytokine profile in serum and cerebrospinal fluid of pediatric and adult spinal muscular atrophy patients and its modulation upon nusinersen treatment

MiR-146a in ALS: Contribution to Early Peripheral Nerve Degeneration and Relevance as Disease Biomarker

Diagnosis and treatment of myasthenia gravis

Suchergebnisse filtern